Description
The 809220 monoclonal antibody specifically recognizes CD56 which is also known as Neural cell adhesion molecule 1 (NCAM-1), Neural cell adhesion molecule (NCAM), or embryonic NCAM (E-NCAM). CD56 (NCAM-1) is a 120-180 kDa type I transmembrane glycoprotein that is encoded by Ncam1 which belongs to the immunoglobulin superfamily (IgSF). Three different isoforms of CD56 (NCAM-1) have been described that vary in their cytoplasmic domains. The 180 kDa long isoform contains five consecutive IgC-like domains followed by two fibronectin type III domains in its extracellular region, a transmembrane sequence and a large cytoplasmic domain. A 140 kDa isoform has a shorter cytoplasmic tail whereas the 120 kDa isoform is glycophosphatidylinositol (GPI)-linked to the cell membrane. CD56 (NCAM-1) functions on cells as a hemophilic or heterophilic adhesion molecule and as a receptor for various ligands including certain growth factors. Throughout development and adulthood, CD56 (NCAM-1) is expressed on various cell types such as neurons where it might play roles in cellular migration, axonal guidance, and synapse formation. It can also be expressed on astrocytes as well as bone marrow neutrophils and some monocytes and might be involved in cellular migration and other functions. Polysialylation of CD56 (NCAM-1) reduces its ability to dimerize and can thereby affect the functions of cells that express it.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
8. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
9. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
10. An isotype control should be used at the same concentration as the antibody of interest.
11. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
